SHANGHAI, Oct. 29, 2015 /PRNewswire/ -- Gilead Sciences,
Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today
announced that they have entered into a strategic partnership to
conduct analytical and stability studies of small-molecule new
chemical entities to support global marketing applications and
commercial products.
Under the agreement, WuXi will equip and operate a dedicated,
fully cGMP-compliant 12,500-square-foot analytical testing facility
in Shanghai. The facility will
provide analytical and stability services, including analytical
method development, transfer and validation for IND/NDA
submissions; commercial API and drug product testing; stability
studies of APIs, drug products for registration, and commercial
products; and reference standard qualification.
"This strategic partnership further strengthens our close,
broad-based collaboration with Gilead over many years," said
Ge Li, PhD, Chairman and CEO of WuXi
PharmaTech. "WuXi is determined to enable our innovative partners
like Gilead through our open-access R&D platform, and we are
very honored to help advance some of the most innovative medicines
faster to patients."
"The opening of this analytical and stability testing center is
an important milestone in the ongoing long-term relationship
between Gilead and WuXi," said Bob
Miller, Vice President of Quality Assurance - Gilead
Sciences.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the
care of patients suffering from life-threatening diseases.
Gilead has operations in more than 30 countries worldwide,
with headquarters in Foster City,
California.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech
provides a broad and integrated portfolio of services throughout
the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi PharmaTech's operating subsidiaries are
known as WuXi AppTec. For more information, please visit:
http://www.wuxiapptec.com.
For more information, please contact:
Gilead Sciences
Amy Flood (Media)
Vice President, Public Affairs, Gilead Sciences
(650) 522-5643
Amy.Flood@gilead.com
WuXi PharmaTech
Ronald Aldridge (Investors)
LaVoieHealthScience
(617) 374-8800 x109
(617) 792-2459
ron_aldridge@wuxiapptec.com
Aaron Shi (Media)
Director, Corporate Communications, WuXi PharmaTech
WuXi PharmaTech
+86-21-5046-4362
aaron_shi@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/gilead-sciences-and-wuxi-pharmatech-announce-collaboration-for-a-dedicated-analytical-and-stability-testing-facility-300168817.html
SOURCE WuXi PharmaTech (Cayman) Inc.